TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02337088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping at 30 seconds
Description: For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping at 60 seconds
Description: For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
Study: NCT01395992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 10 mg tablet, SL BID for 182 days
Study: NCT02666014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal of neuromuscular blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal of neuromuscular blockade
Study: NCT04347083

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic test
Description: Muscle spindle- based reflex latency will be measured
Study: NCT02543138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trocar
Description: Closed thoracostomy using the new trocar
Study: NCT02443064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on.
Study: NCT03892447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: Alprostadil 0.2\~0.3ug/kg.h,iv,1h/d,14d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Ferulate
Description: Sodium Ferulate 2\~6mg/kg.d,iv,14d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine3～5 ug/kg·min,iv,3 h/d,14d
Study: NCT03254966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets
Study: NCT02257736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive 240 mg (4\*60 mg tablets) of apalutamide once daily orally.
Study: NCT03254966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT03087006

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation (ASTM)
Description: Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
Study: NCT02257736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone acetate
Description: Participants will receive 1000 mg (4\*250 mg tablets) of abiraterone acetate (AA) once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 5 mg tablet of prednisone twice daily orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Participants will receive 5 mg tablet of prednisone twice daily orally.
Study: NCT03087006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care includes usual care of the participants including dry eye disease medications
Study: NCT03287258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 program
Description: The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one program
Description: The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
Study: NCT01298492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659
Description: 75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
Study: NCT03880201

Intervention type: PROCEDURE
Intervention: ultrasound guided supraclavicular block
Description: The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves.

Intervention type: DEVICE
Intervention: Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)
Description: Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
Study: NCT02340663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOVA Bite Splint
Description: Over-the-counter thermoplastic bite splint blank, heated, molded to fit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Michigan Bite Splint
Description: Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
Study: NCT01078805

Intervention type: DRUG
Intervention: FORTEO
Description: prescribed in accordance with usual clinical practice for up to 24 months
Study: NCT00511680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Based In-Home Intervention
Description: The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
Study: NCT02997592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpinCare
Description: The burn wound is treated using the SpinCare Systen
Study: NCT00704262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus hydrocortisone (LEO 80190)
Description: Once daily application
Study: NCT01184937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs.
Study: NCT04465682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Dip Home-Based Dipstick Analyzer
Description: Dip Home-Based Dipstick Analyzer The Dip Home-Based Dipstick Analyzer is a prescription, in-vitro diagnostic, home use device, which qualitatively and semi-quantitatively measures 10 urine analytes. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm.
Study: NCT01074138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391
Description: KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
Study: NCT01331304

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium
Description: 600-900mg per day over 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: Quetiapine
Description: 100-800mg a day over 6 months
Study: NCT01230957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (Low-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (Low-dose without adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose without adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 0.9% normal saline
Description: 0.5 mL, Intramuscular on Days 0, 7, and 30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 7, and 180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoids A and B (high-dose with adjuvant)
Description: 0.5 mL, Intramuscular on Days 0, 30, and 180
Study: NCT03726684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coding strategy for cochlear implants
Description: Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
Study: NCT00693160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: single intrathecal injection of ketorolac 2 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subject will receive a placebo (preservative free normal saline) spinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: All subjects will receive a remifentanil infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: remifentanil
Description: All subjects will receive a remifentanil infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Topical capsaicin pain model utilized for each subject

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: Topical capsaicin pain model utilized for each subject
Study: NCT04435223

Intervention type: BIOLOGICAL
Intervention: biological assays in particular on the lipid metabolism
Description: bioassays carried out on samples already collected and conserved

Intervention type: BIOLOGICAL
Intervention: biological assays in particular on the lipid metabolism
Description: bioassays carried out on samples already collected and conserved
Study: NCT05728294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block with ropivacaine 0.5%, 20 ml
Description: Femoral nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve block with ropivacaine 0.5%, 20 ml
Description: Sciatic nerve block under ultrasound guidance with ropivacaine 0.5%, 20 ml
Study: NCT02803073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone Cypionate Intramuscular injections will be administered weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline Intramuscular injections will be administered weekly
Study: NCT01676285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04177719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: oxytocin will be given intranasally. The order of administration will be counterbalanced

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be given intranasally. The order of administration will be counterbalanced
Study: NCT02544412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: novel mindfulness-based well-being training
Study: NCT04147351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection; bevacizumab Injection
Description: a PD-L1 inhibitor; anti-angiogenesis
Study: NCT00317148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA capsule
Description: One capsule of DHEA
Study: NCT03198130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2810
Description: Intravenous (IV) use
Study: NCT00727363

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
Study: NCT01014585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Milnacipran tablets administered orally twice daily
Study: NCT04218097

Intervention type: OTHER
Intervention: Study questionnaire
Description: Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.

Intervention type: OTHER
Intervention: Study questionnaire
Description: Monitoring - data collection: Sending of an information form and the study questionnaire, the YFAS and Hospital Anxiety and Depression (HAD) scale by post within a follow-up period of 24 to 36 months. With a stamped envelope for the answer and a telephone reminder if necessary.
Study: NCT02257736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to apalutamide once daily orally.
Study: NCT02154425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast milk sampling
Description: Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
Study: NCT03418532

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MP0250 DARPin® drug candidate, Osimertinib
Description: Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
Study: NCT02584244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Study: NCT04072757

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Session One: Loving Food That Loves You Back - Food as Fuel~* connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~* seasonal fruits \& vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~* quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~* choose healthier foods Session Five: Taste Bud Rehab~* reduce foods high in sugar and salt.Mind-body connection Session Six: Batch \& One Ingredient Cooking~* making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~* prepare healthier desserts Session Eight: Family Meal Practices~* healthy eating habits in children Session Nine: Snacks as Mini Meals~* make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~* healthy up favorite recipes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided.
Study: NCT02584244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Study: NCT02817087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation -On
Description: Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation -Off
Description: Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
Study: NCT02242500

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronally Advanced Flap

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucograft
Study: NCT01332682

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counseling
Description: Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training and Nutrition Counseling
Description: Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
Study: NCT02591433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Undergo JeffQuit group therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Group Therapy
Description: Undergo JeffQuit group therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02584244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device
Study: NCT01543581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib
Description: Oral vismodegib, 150mg per day for 12 weeks.
Study: NCT03649295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Speech Therapy
Description: Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
Study: NCT01543581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03649295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Speech Therapy
Description: Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
Study: NCT00065429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-10901
Description: I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease.
Study: NCT02584244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LUM 2.6 Imaging Device